Integrated Drug Discovery: Hit To PCC In 16 Months

In this case study, BioDuro partnered with a biotechnology company to rapidly advance a kinase inhibitor program targeting inflammatory disease from early hit identification through selection of a preclinical candidate (PCC) in only 16 months. The accelerated timeline highlights the strength of BioDuro’s integrated drug discovery platform, which combines medicinal chemistry, biology, DMPK, and translational expertise within a coordinated and highly efficient workflow.

By using iterative design, rapid data generation, and cross-functional collaboration, the team quickly optimized potency, selectivity, pharmacokinetic properties, and overall developability, while minimizing delays typically associated with traditional discovery models. The project shows how a streamlined, strategically integrated approach can significantly reduce development timelines, helping biotech innovators move promising therapeutic candidates toward preclinical advancement more quickly, with greater confidence, and with greater operational efficiency.